We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

114 hedge funds and large institutions have $342M invested in Sutro Biopharma in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 35

0.36% more ownership

Funds ownership: 8.62% → 8.98% (+0.36%)

3% less funds holding

Funds holding: 117 → 114 (-3)

11% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 27

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

42% less capital invested

Capital invested by funds: $593M → $342M (-$251M)

Holders
114
Holders Change
-3
Holders Change %
-2.56%
% of All Funds
1.8%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
24
Increased
40
Reduced
35
Closed
27
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$24M
2
SCM
Suvretta Capital Management
New York
+$12.3M
3
State Street
State Street
Massachusetts
+$10M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$5.9M
5
Franklin Resources
Franklin Resources
California
+$4.57M

Top Sellers

Rank Fund Capital Flow
1
SHI
SV Health Investors
Massachusetts
-$27.1M
2
FM
Frazier Management
Washington
-$26.4M
3
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$16.6M
4
OM
Opaleye Management
Massachusetts
-$5.61M
5
FLAM
First Light Asset Management
Minnesota
-$5.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Pentwater Capital Management
Florida
$2.06M +$190K +2,000 +9%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$1.96M +$899K +9,444 +66%
AllianceBernstein
28
AllianceBernstein
Tennessee
$1.69M -$91.8K -965 -4%
PHP
29
Parkman Healthcare Partners
Connecticut
$1.64M -$203K -2,137 -10%
N
30
Nuveen
North Carolina
$1.48M +$37.4K +393 +2%
AIIC
31
AJU IB Investment Company
South Korea
$1.44M – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$1.4M +$1.09M +11,461 +204%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$1.35M +$796K +8,366 +103%
TCM
34
Tekla Capital Management
Massachusetts
$1.35M -$1.56M -16,393 -50%
Two Sigma Investments
35
Two Sigma Investments
New York
$1.34M +$474K +4,983 +44%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.24M +$9.52K +100 +0.7%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
37
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.23M +$1.43M +15,000 New
Nomura Holdings
38
Nomura Holdings
Japan
$1.07M -$916K -9,630 -43%
Charles Schwab
39
Charles Schwab
California
$984K +$96.3K +1,012 +9%
PAM
40
Panagora Asset Management
Massachusetts
$979K -$250K -2,629 -18%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$947K +$562K +5,910 +105%
KCM
42
Kennedy Capital Management
Missouri
$940K -$130K -1,362 -11%
UBS Group
43
UBS Group
Switzerland
$907K +$1.05M +11,033 New
Two Sigma Advisers
44
Two Sigma Advisers
New York
$879K +$120K +1,260 +13%
OM
45
Opaleye Management
Massachusetts
$740K -$5.61M -59,002 -87%
CSS
46
Cubist Systematic Strategies
Connecticut
$703K +$814K +8,557 New
DCM
47
DAFNA Capital Management
California
$696K +$378K +3,970 +88%
PP
48
PDT Partners
New York
$665K +$770K +8,087 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$630K +$55.2K +580 +8%
Walleye Capital
50
Walleye Capital
New York
$523K -$112K -1,180 -16%
1
2
3 4 5

STRO Hedge Fund Activity: Q1 2022 in Review

114 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2022, worth a combined $342M — down 42% from $593M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of STRO and 24 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 40 added.

The largest buyer was BVF Inc, adding an estimated $24M. The largest seller was SV Health Investors, exiting entirely with an estimated $27.1M sold.

  • 114 institutional investors held Sutro Biopharma (STRO) as of Q1 2022, down from 117 in Q4 2021.
  • Funds reported $342M of Sutro Biopharma stock for Q1 2022, down 42% quarter-over-quarter.
  • 24 funds opened new Sutro Biopharma positions in Q1 2022 and 27 closed out, a net change of -3 holders.
  • The largest Sutro Biopharma buyer in Q1 2022 was BVF Inc, an estimated $24M added.
  • The largest Sutro Biopharma seller in Q1 2022 was SV Health Investors, an estimated $27.1M sold.

Based on aggregated 13F filings for Q1 2022.